KIT and melanoma: Our observations will open new fields for developing therapies for cancers that express mutant Kit, such as mast cell tumours, GISTs, acute myeloid leukemia, and melanomas and will be helpful for understanding the spatiotemporal regulation of tyrosine phosphorylation signalling.